Trials / Unknown
UnknownNCT01730209
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- 4 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
Tuberous sclerosis complex (TSC) is a genetic disease that leads to mental retardation in over 50% of patients, and to learning problems, behavioral problems, autism and epilepsy in up to 90% of patients. The underlying deficit of TSC, loss of inhibition of the mammalian target of rapamycin (mTOR) protein due to dysfunction of the tuberin/hamartin protein complex, can be rescued by everolimus. Everolimus has been registered as treatment for renal cell carcinoma and giant cell astrocytoma (SEGA). Evidence in human and animal studies suggests that mTOR inhibitors improve learning and development in patients with TSC.
Detailed description
Randomized double-blind placebo controlled intervention study in children with TSC between age 4 and 15 years with an intelligence quotient (IQ) estimated \<80 and/or special schooling and/or autism spectrum disorder and/or learning disability requiring remedial teaching. Patients are randomised to receive everolimus or placebo during a period of 12 months.
Conditions
- Tuberous Sclerosis Complex
- TSC Related Cognitive Disability
- TSC Related Autism
- TSC Related Learning Problems
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Everolimus once daily titrated to trough levels of 5-10 ng/ml. |
| DRUG | Placebo |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-11-01
- Completion
- 2016-11-01
- First posted
- 2012-11-21
- Last updated
- 2015-05-05
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01730209. Inclusion in this directory is not an endorsement.